Furthermore, the exploration of ANKHD1 inhibitor treatment could provide novel therapy strategies for pancreatic cancer, especially in combination with MDM2 inhibitor treatment, which should be verified by further research. Here, ANKHD1 is linked to familial pancreatic carcinoma.